| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Other income | 44.5 | 201.0 | 31.1 |
| Total income | 3945.0 | 6248.0 | 3419.0 |
| Exceptional items | 184.0 | 1385.0 | 0.0 |
| Net profit | 403.0 | 610.0 | 348.0 |
| Operating margin | 13.5% | 15.5% | 13.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +15.80% |
|---|---|
| Net profit, quarter on quarter | -33.90% |
BSE results filing, NSE: GLENMARK. Figures extracted from the filing.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,441.50
- Market cap
- ₹68,905 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 38.3×Sector 49.8×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in various dosages. This launch expands the company's injectable portfolio and presence in the U.S. hospital market.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received U.S. FDA approval for its Fluticasone Propionate Nasal Spray. The product will be distributed in the U.S. market.